Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen and prostate cancer.

S B Rosalki1, F J Rutherford

  • 1Omnilabs (UK) Ltd, 27 Harley Street, London W1N 1DA, UK.

International Journal of Clinical Practice
|February 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carbohydrate-deficient transferrin: a marker of alcohol abuse.

International journal of clinical practice·2004
Same author

Genetic haemochromatosis.

International journal of clinical practice·2002
Same author

C-reactive protein.

International journal of clinical practice·2001
Same author

The advancement of science in Brazil.

Anais da Academia Brasileira de Ciencias·2000
Same author

Biochemical identification of alcohol abuse.

International journal of clinical practice·1999
Same author

Porphyria and its investigation.

International journal of clinical practice·1998

Serum prostate-specific antigen (PSA) testing aids in diagnosing prostate cancer and monitoring treatment. Measuring free PSA levels helps differentiate cancer from benign conditions, improving patient management.

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Background:

  • Serum prostate-specific antigen (PSA) is a key biomarker for prostate health.
  • PSA levels can be elevated in both prostate cancer and benign prostatic conditions.
  • Early detection of prostate cancer is crucial for effective treatment.

Purpose of the Study:

  • To evaluate the utility of serum PSA measurements in diagnosing prostate cancer.
  • To explore methods for differentiating prostate cancer from benign prostatic hypertrophy (BPH).
  • To assess the role of PSA in monitoring prostate cancer treatment and surveillance.

Main Methods:

  • Analysis of serum PSA levels in patients with lower urinary tract symptoms and asymptomatic individuals.
  • Correlation of PSA levels with prostatic malignancy and benign prostatic disease.

Related Experiment Videos

  • Utilizing serial PSA measurements, prostatic volume correction, and free PSA (fPSA) fraction analysis.
  • Monitoring PSA trends during and after prostate cancer treatment.

    • Main Results:

    • Elevated serum PSA is observed in approximately 60% of early prostate cancer cases and 20% of benign prostatic disease cases.
    • Slightly elevated PSA levels can be challenging to interpret; fPSA measurement aids differentiation.
    • Serial PSA measurements and fPSA levels are valuable for distinguishing prostate cancer from BPH.
    • Serial PSA monitoring is effective for assessing treatment response and post-treatment surveillance.

    Conclusions:

    • Serum PSA measurement is a valuable tool for prostate cancer screening and investigation.
    • Free PSA fraction analysis significantly improves the diagnostic accuracy in cases of equivocal PSA levels.
    • PSA monitoring is essential for managing prostate cancer patients throughout their treatment journey.